SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Callisto Pharmaceuticals
An SI Board Since December 2005
Posts SubjectMarks Bans Symbol
19 1 0 KAL
Emcee:  John McCarthy Type:  Unmoderated
Introduction Market Data Compact
Callisto Pharmaceuticals develops drugs for the treatment of cancer. Its two primary drug candidates are Annamycin, which treats relapsed leukemia, and Atiprimod, a treatment for bone resorption and multiple myeloma (blood cancer). The company has licensing agreements with AnorMED and M.D. Anderson Cancer Center. It also acquired the rights to Site Directed Intercalation (SDI) from Houston Pharmaceuticals. The technology is used to identify potential drug candidates. In addition to its work in cancer treatment, Callisto is collaborating with Rockefeller University to develop defenses against biological weapons.
biz.yahoo.com

==========================================

Callisto Pharmaceuticals Announces Poster Presentation on Atiprimod at Major Scientific Meeting in December
Thursday December 1, 4:01 pm ET
Research on Atiprimod's Effect on Leukemia Cells to Be Presented at American Society of Hematology Annual Meeting
biz.yahoo.com

==========================================

British Journal of Cancer (2005) 93, 70-80.
doi:10.1038/sj.bjc.6602637 Published online 21 June 2005

Atiprimod blocks STAT3 phosphorylation and induces apoptosis in multiple myeloma cells

M Amit-Vazina1, S Shishodia1, D Harris1, Q Van1, M Wang2, D Weber2, R Alexanian2, M Talpaz1, B B Aggarwal1 and Z Estrov1

1Department of Bioimmunotherapy, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA

2Department Lymphoma/Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA

Correspondence to: Dr Z Estrov, Department of Leukemia, Unit 428, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA. E-mail: zestrov@mdanderson.org

Revised 8 April 2005; accepted 2 May 2005; published online 21 June 2005

Multiple myeloma (MM) accounts for 1 % of all cancer deaths. Although treated aggressively, almost all myelomas eventually recur and become resistant to treatment. Atiprimod (2-(3-Diethylaminopropyl)-8,8-dipropyl-2-azaspiro[4,5] decane dimaleate) has exerted anti-inflammatory activities and inhibited oeteoclast-induced bone resorption in animal models and been well tolerated in patients with rheumatoid arthritis in phase I clinical trials. Therefore, we investigated its activity in MM cells and its mechanism of action. We found that Atiprimod inhibited proliferation of the myeloma cell lines U266-B1, OCI-MY5, MM-1, and MM-1R in a time- and dose-dependent manner. Atiprimod blocked U266-B1 myeloma cells in the G0/G1 phase, preventing cell cycle progression. Furthermore, Atiprimod inhibited signal transducer and activator of transcription (STAT) 3 activation, blocking the signalling pathway of interleukin-6, which contributes to myeloma cell proliferation and survival, and downregulated the antiapoptotic proteins Bcl-2, Bcl-XL, and Mcl-1. Incubation of U266-B1 myeloma cells with Atiprimod induced apoptosis through the activation of caspase 3 and subsequent cleavage of the DNA repair enzyme poly(adenosine diphosphate-ribose) polymerase. Finally, Atiprimod suppressed myeloma colony-forming cell proliferation in fresh marrow cells from five patients with newly diagnosed MM in a dose-dependent fashion. These data suggest that Atiprimod has a role in future therapies for MM.

Keywords: multiple myeloma; signal transduction; clonogenic assay; nuclear factor B, apoptosis

nature.com

==========================================

EquityNet Research Initiates Coverage of Callisto Pharmaceuticals with Buy Rating and Projected 12-Month Share Price of $3.45
Friday December 2, 4:01 pm ET
Report Cites Key Strategic Research Partnerships and Demand for New Anti-Cancer Drugs and Novel Treatments
equitynet.net

==========================================

clinicaltrials.gov

==========================================
 Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
19The company has had new releases and seems to be making an effort to move but tiG. Stewart-4/13/2006
18Callisto Outlines Achievements in Development of Anti-Cancer Drug Candidates andJohn McCarthy-12/8/2005
17Press Release Source: Callisto Pharmaceuticals, Inc. Callisto Launches MilestoJohn McCarthy-12/6/2005
16Callisto's CEO Dr. Gary Jacob Discusses Launch of Human Clinical Trial of CaJohn McCarthy-12/6/2005
15Message 21940489Julius Wong-12/3/2005
14About STAT3 - Part 2 1: Oncogene. 2005 Oct 3; [Epub ahead of print] Related ArtJohn McCarthy-12/3/2005
13About STAT3 - Part 1 Note: Did a search on STAT3 and Cancer. Decided this abstJohn McCarthy-12/3/2005
122005 - Atiprimod blocks STAT3 phosphorylation and induces apoptosis in multiple John McCarthy-12/3/2005
111999 - SK&F 106615 (atiprimod). 1: Toxicol Appl Pharmacol. 1999 Aug 15;159John McCarthy-12/3/2005
101999 - Atiprimod (SK&F 106615) 1: Int J Immunopharmacol. 1999 Mar;21(3):161John McCarthy-12/3/2005
91998 - SK&F 106615 Inflamm Res. 1998 Feb;47(2):56-61. Related Articles, LiJohn McCarthy-12/3/2005
81997 - SK&F 106615 1: Immunopharmacology. 1997 Aug;37(1):53-61. Related ArtJohn McCarthy-12/3/2005
72000 - Atiprimod (AnorMED). Lakings DB. Drug Safety Evaluation Consulting Inc,John McCarthy-12/3/2005
62004 - Atiprimod is an inhibitor of cancer cell proliferation and angiogenesis. John McCarthy-12/3/2005
52005 - Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanaminJohn McCarthy-12/3/2005
41999 - Int J Immunopharmacol. 1999 Mar;21(3):161-76. Related Articles, Links John McCarthy-12/3/2005
3News Release from: Callisto Pharmaceuticals Edited by the Laboratorytalk EditorJohn McCarthy-12/3/2005
2[111] A Phase I, Multi-Center, Dose Escalation Study of Atiprimod in Patients wJohn McCarthy-12/3/2005
1[249] In Vivo Anti-Tumor Activity of Atiprimod on SCID Models of Multiple MyelJohn McCarthy-12/3/2005
 Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News